– USA, MA – Pillar Biosciences, an innovative next-generation sequencing solutions in-vitro diagnostics company, today announced the appointment of Randy Pritchard as CEO, succeeding founder, industry veteran, and renowned scientific innovator, Dr. Gang Song who will transition to the role of Chairman of the Board of Directors.
“On behalf of the Board, I am excited to welcome Randy to lead Pillar Biosciences in its next stage of growth. He brings invaluable experience, as we accelerate our growth with the launch of our oncoReveal Dx Lung and Colon Cancer Assay, which received FDA Premarket Approval recently,” said Co-Founder and Chairman, Dr. Gang Song. “Pillar Biosciences was founded with a mission to make precision medicine accessible for all, by simplifying clinical next-generation sequencing and bringing testing closer to the patient.”
“The Board was impressed by Randy’s depth of understanding of the diagnostics space and what drives growth, as well as his leadership experience,” said Simone Song, Founder, ORI Capital. “His ability to quickly analyze a business, develop and execute on the growth strategy was truly remarkable. I am fully confident that Randy will be an outstanding leader for Pillar at this next stage of growth.”
About Dr. Randy Pritchard
Dr. Randy Pritchard brings to Pillar Biosciences more than 24 years of healthcare experience, as a diagnostics executive who has deep experience in corporate and commercial strategy, sales, and marketing, driving growth through innovation. He has held positions of increasing responsibilities, including SVP of US Diagnostics marketing, SVP & Lifecycle Leader at the divisions of POC Diagnostic & Core Reagents, and VP of Marketing at Centralized Diagnostics at Roche Diagnostics.
“I look forward to working with Gang and the Pillar Biosciences team to accelerate the adoption of oncoReveal Dx and bring more innovative NGS cancer testing products to patients, in particular in the area of liquid biopsy,” said CEO, Randy Pritchard. “Pillar has grown to over 150 dedicated team members in the US and China, and I look forward to leading the company in its next stage of growth to become a global clinical cancer NGS diagnostics company.”
About Pillar Biosciences
Pillar Biosciences is a global oncology solutions company delivering in-vitro diagnostics that provide accurate, robust, timely, clinically actionable insights to guide treatment decisions throughout a patient’s continuum of care. Our mission is to enable access to high-quality, affordable, specialty NGS testing, performed by any NGS laboratory as clinical-grade tests, closer to home, for all patients. Pillar has operations in Natick, MA, and Shanghai, China.
For more information: https://pillar-biosciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
